JP2022532927A5 - - Google Patents
Info
- Publication number
- JP2022532927A5 JP2022532927A5 JP2021569354A JP2021569354A JP2022532927A5 JP 2022532927 A5 JP2022532927 A5 JP 2022532927A5 JP 2021569354 A JP2021569354 A JP 2021569354A JP 2021569354 A JP2021569354 A JP 2021569354A JP 2022532927 A5 JP2022532927 A5 JP 2022532927A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- seq
- antibody
- pharmaceutical formulation
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852643P | 2019-05-24 | 2019-05-24 | |
| US62/852,643 | 2019-05-24 | ||
| PCT/US2020/034438 WO2020243031A1 (en) | 2019-05-24 | 2020-05-24 | Stabilized formulations containing anti-angptl3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022532927A JP2022532927A (ja) | 2022-07-20 |
| JP2022532927A5 true JP2022532927A5 (https=) | 2023-05-09 |
| JP7783051B2 JP7783051B2 (ja) | 2025-12-09 |
Family
ID=72179136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569354A Active JP7783051B2 (ja) | 2019-05-24 | 2020-05-24 | 抗ａｎｇｐｔｌ３抗体を含有する安定化製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12559551B2 (https=) |
| EP (1) | EP3976647A1 (https=) |
| JP (1) | JP7783051B2 (https=) |
| KR (1) | KR20220011727A (https=) |
| AU (1) | AU2020282956A1 (https=) |
| BR (1) | BR112021023501A2 (https=) |
| CA (1) | CA3139333A1 (https=) |
| CL (1) | CL2021003026A1 (https=) |
| CO (1) | CO2021016183A2 (https=) |
| EA (1) | EA202193240A1 (https=) |
| IL (1) | IL288153A (https=) |
| MA (1) | MA56049A (https=) |
| MX (1) | MX2021014332A (https=) |
| PH (1) | PH12021552788A1 (https=) |
| SG (1) | SG11202112256SA (https=) |
| WO (1) | WO2020243031A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| IL308643B2 (en) | 2017-05-05 | 2025-02-01 | Regeneron Pharma | Auto-injector |
| JP2024509937A (ja) * | 2021-03-09 | 2024-03-05 | ジーアイ・イノベイション・インコーポレイテッド | Ｉｇｅ ｆｃ受容体のアルファサブユニットの細胞外ドメインを含む融合タンパク質の製剤 |
| EP4375298A4 (en) * | 2021-07-21 | 2025-02-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| EP4453210A1 (en) | 2021-12-22 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors |
| IL316249A (en) | 2022-05-02 | 2024-12-01 | Novo Nordisk As | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
| EP4615974A1 (en) | 2022-11-10 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors |
| WO2025075970A1 (en) | 2023-10-02 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| EP1151092B1 (en) | 1999-02-12 | 2008-12-31 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| NZ527408A (en) | 2001-02-22 | 2005-04-29 | Skyepharma Canada Inc | Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia |
| EP1451578B1 (en) | 2001-11-16 | 2013-08-21 | Genentech, Inc. | Use of angptl3 antagonists for the treatment of liver diseases |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| AU2006223579A1 (en) | 2005-03-11 | 2006-09-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
| WO2008073300A2 (en) | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| EP2398476B1 (en) | 2009-02-23 | 2018-02-07 | Nanorx, Inc. | Policosanol nanoparticles |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| JP5602850B2 (ja) | 2009-07-14 | 2014-10-08 | ザ スクリプス リサーチ インスティテュート | 間葉幹細胞分化 |
| CN102753186B (zh) | 2010-01-08 | 2016-09-14 | Isis制药公司 | 血管生成素样3表达的调节 |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| EP2723758B1 (en) | 2011-06-21 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| CN104768578A (zh) | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| US20160002315A1 (en) | 2013-03-14 | 2016-01-07 | Uab Research Foundation | Apolipoprotein mimetics and uses thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US10494442B2 (en) | 2013-06-07 | 2019-12-03 | Sanofi Biotechnology | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| PT3087183T (pt) | 2013-12-24 | 2020-10-08 | Ionis Pharmaceuticals Inc | Modulação da expressão da proteína relacionada com angiopoietina 3 |
| US9382540B2 (en) | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
| CA2955304C (en) | 2014-07-16 | 2023-12-12 | Sanofi Biotechnology | Methods for treating high cardiovascular risk patients with hypercholesterolemia |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| MA44234B1 (fr) | 2016-02-17 | 2023-10-31 | Regeneron Pharma | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 |
| MA43734A (fr) | 2016-03-03 | 2018-11-28 | Regeneron Pharma | Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 |
| RS62769B1 (sr) | 2016-04-08 | 2022-01-31 | Regeneron Pharma | Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 |
| FI3448426T3 (fi) | 2016-04-28 | 2025-07-18 | Regeneron Pharma | Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CA3188213A1 (en) | 2020-08-07 | 2022-02-10 | Robert C. Pordy | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
-
2020
- 2020-05-22 US US16/882,280 patent/US12559551B2/en active Active
- 2020-05-24 PH PH1/2021/552788A patent/PH12021552788A1/en unknown
- 2020-05-24 AU AU2020282956A patent/AU2020282956A1/en active Pending
- 2020-05-24 KR KR1020217042347A patent/KR20220011727A/ko not_active Ceased
- 2020-05-24 BR BR112021023501A patent/BR112021023501A2/pt unknown
- 2020-05-24 MA MA056049A patent/MA56049A/fr unknown
- 2020-05-24 SG SG11202112256SA patent/SG11202112256SA/en unknown
- 2020-05-24 MX MX2021014332A patent/MX2021014332A/es unknown
- 2020-05-24 CA CA3139333A patent/CA3139333A1/en active Pending
- 2020-05-24 JP JP2021569354A patent/JP7783051B2/ja active Active
- 2020-05-24 EP EP20760579.1A patent/EP3976647A1/en active Pending
- 2020-05-24 EA EA202193240A patent/EA202193240A1/ru unknown
- 2020-05-24 WO PCT/US2020/034438 patent/WO2020243031A1/en not_active Ceased
-
2021
- 2021-11-16 IL IL288153A patent/IL288153A/en unknown
- 2021-11-16 CL CL2021003026A patent/CL2021003026A1/es unknown
- 2021-11-29 CO CONC2021/0016183A patent/CO2021016183A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532927A5 (https=) | ||
| US12544438B2 (en) | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | |
| JP2024016177A5 (https=) | ||
| CN103458926B (zh) | 改进的高浓度抗TNF α 抗体液体制剂 | |
| FI4249512T3 (fi) | Stabiili vasta-aineformulaatio | |
| JP2008528638A5 (https=) | ||
| JP2025172841A5 (https=) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| RU2008141433A (ru) | Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста | |
| RS56210B1 (sr) | Formulacije sa visokom koncentracijom antitela | |
| JP2024544523A5 (https=) | ||
| JP2024531151A5 (https=) | ||
| RU2019102943A (ru) | Составы на основе антитела | |
| JP2024515968A5 (https=) | ||
| WO2019020069A1 (zh) | 一种sost抗体药物组合物及其用途 | |
| RU2020111574A (ru) | Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом | |
| JP2021523881A5 (https=) | ||
| JP2020531523A5 (https=) | ||
| JP2023502398A5 (https=) | ||
| JP2024538140A5 (https=) | ||
| JP2022519796A (ja) | 抗ｐｃｓｋ９抗体を含む安定製剤 | |
| JP2022519796A5 (https=) | ||
| JP2023533963A5 (https=) | ||
| IL312401A (en) | Methods of treating crohn's disease with anti-il23 specific antibody | |
| JP2024500912A5 (https=) |